Form D · Biotechnology

ZetaRx Biosciences, Inc.

Seattle, WA · CIK 0001508561

Offering snapshot reported Aug 23, 2013 · SEC filing

Reported sold
$2M
Offering amount: $12M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 30, 2012
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1M$2MDec 12, 2012: $2,000,000.00Dec 12, 2012Aug 23, 2013: $2,000,000.00Aug 23, 2013

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 23, 2013Amendment$2,000,000$0vs Dec 12, 20124SEC filing
Dec 12, 2012Initial$2,000,000No comparison4SEC filing
Dec 22, 2010Initial$750,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$64.4K
Form D file number
021-188260
$60,000 in cash and 20,000 shares of the Common Stock of Issuer that have a fair market value of $.22 per share.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Monarch Bay Securities, LLC141391

Source: Form D, filed Aug 23, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gordon M. Binder Director, Executive
David A. Dull Director
Jack Kavanaugh Director, Executive
Ken Mohler Executive
Edmund M. Olivier Director
D. Verne Sharma Director
Cynthia Shumate Executive
Robert Snukal Director
Werner F. Wolfen Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1601 5 Th Avenue, Suite 2060
Seattle, WA, 98101